bluebird bio, Inc. (NASDAQ:BLUE) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC lifted its stake in shares of bluebird bio, Inc. (NASDAQ:BLUEGet Rating) by 1,185.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 129,729 shares of the biotechnology company’s stock after purchasing an additional 119,638 shares during the period. Walleye Capital LLC’s holdings in bluebird bio were worth $629,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Advisor Group Holdings Inc. lifted its holdings in bluebird bio by 24.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 18,058 shares of the biotechnology company’s stock worth $180,000 after buying an additional 3,543 shares during the last quarter. Bank of America Corp DE lifted its stake in bluebird bio by 513.4% during the fourth quarter. Bank of America Corp DE now owns 694,929 shares of the biotechnology company’s stock worth $6,942,000 after purchasing an additional 581,642 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in bluebird bio by 34.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 453,869 shares of the biotechnology company’s stock worth $4,535,000 after purchasing an additional 116,621 shares during the period. Teacher Retirement System of Texas increased its stake in bluebird bio by 18.5% during the fourth quarter. Teacher Retirement System of Texas now owns 12,817 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 2,004 shares during the last quarter. Finally, Citigroup Inc. increased its stake in bluebird bio by 240.7% during the fourth quarter. Citigroup Inc. now owns 507,458 shares of the biotechnology company’s stock valued at $5,070,000 after purchasing an additional 358,494 shares during the last quarter. 78.25% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Stock Performance

NASDAQ:BLUE opened at $6.17 on Thursday. The stock has a market cap of $475.84 million, a price-to-earnings ratio of -0.74 and a beta of 1.12. bluebird bio, Inc. has a 1 year low of $2.87 and a 1 year high of $25.39. The business has a fifty day moving average of $5.78 and a 200-day moving average of $4.73.

bluebird bio (NASDAQ:BLUEGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.31) by $0.02. The business had revenue of $1.52 million during the quarter, compared to the consensus estimate of $6.47 million. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. On average, equities research analysts predict that bluebird bio, Inc. will post -4.66 EPS for the current year.

Insider Transactions at bluebird bio

In related news, CEO Andrew Obenshain sold 21,805 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the transaction, the chief executive officer now owns 247,131 shares in the company, valued at $1,084,905.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Andrew Obenshain sold 21,805 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the sale, the chief executive officer now owns 247,131 shares in the company, valued at $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jason Cole sold 14,194 shares of the firm’s stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $5.53, for a total value of $78,492.82. Following the transaction, the insider now directly owns 189,546 shares of the company’s stock, valued at approximately $1,048,189.38. The disclosure for this sale can be found here. In the last three months, insiders sold 44,805 shares of company stock valued at $213,636. Company insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BLUE shares. The Goldman Sachs Group raised their price target on shares of bluebird bio from $2.00 to $3.00 and gave the stock a “sell” rating in a research report on Friday, August 19th. SVB Leerink raised their target price on shares of bluebird bio from $8.00 to $10.00 and gave the stock a “market perform” rating in a report on Thursday, August 18th. Raymond James upped their target price on bluebird bio from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Barclays raised bluebird bio from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $3.00 to $5.00 in a report on Friday, August 5th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.25.

About bluebird bio

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Featured Articles

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUEGet Rating).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.